Alliance Researcher: 'Herceptin works - and it works for a long period of time'

After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone. These findings, published in the Journal o


UPCOMING MEETINGS

2014 Fall Group Meeting | November 5-8
Loews Hotel Chicago O'Hare, Rosemont, IL 60018
open to all Alliance members
Schedule
Registration
Agendas

2015 Summer Group Meeting | May 14-16
Loews Hotel Chicago O'Hare, Rosemont, IL 60018
open to all Alliance members

TWEETS

FROM THE NCI

RSS Feed Widget